Bejelentkezés Regisztrálj ingyen

Albireo Pharma Inc Ret. az eszközökre

Mi az Albireo Pharma Inc Ret. az eszközökre?

A Ret. az eszközökre az Albireo Pharma Inc - -47.11%

Mi a Ret. az eszközökre meghatározása?



A Eszközök megtérülése azt jelzi, hogy a vállalat eszközeinek jövedelmezősége mennyire nyereséges. Ezt a nettó jövedelem átlagösszeggel való elosztásával számítják ki.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. az eszközökre a Health Care szektor a NASDAQ-on cégekben a Albireo Pharma Inc -hoz képest

Mit csinál Albireo Pharma Inc?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

ret. az eszközökre -hoz hasonló cégek Albireo Pharma Inc